⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALLR News
Allarity Therapeutics, Inc. Common Stock
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
globenewswire.com
ALLR
Form 8-K
sec.gov
ALLR
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
globenewswire.com
ALLR
Form 8-K
sec.gov
ALLR
Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
globenewswire.com
ALLR
Form 8-K
sec.gov
ALLR
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
globenewswire.com
ALLR
Form 8-K
sec.gov
ALLR
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
globenewswire.com
ALLR
PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
AZN
MRK
JNJ
PFE
ABBV
GSK
ALLR
SNY
CURI
ORIC
EXEL
ABSI
LLY
TLX
FPH
BMY
SNX
XNCR
ZENA
ARVN
MGNX
DASH
VERU
GILD
EVGN
GEN
AMGN
MIR
RXRX
BG
MTX
BIO